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I should start with a disclaimer: I was a strong supporter of
Barack Obama during the recent US presidential campaign,
and I remain a strong supporter of the President-elect today.
That may open me to charges of bias as far as this particular
column is concerned, because I’m going to be lauding one of
his recent decisions. But another disclaimer I probably
should include is that I am a life scientist, and that admis-
sion may reveal additional prejudice, because what I am
going to say will be self-serving in that it is meant to promote
the life sciences. However, I think my argument will stand
up to objective scrutiny. See if you agree.
I learned in mid-December that President-elect Obama
would choose, for the dual position of presidential science
advisor and head of the Office of Science and Technology
Policy (OSTP), John Holdren, a Harvard physicist and out-
spoken critic of the Bush Administration’s science policies.
Holdren’s primary appointment is not in the physics depart-
ment - he is the Teresa and John Heinz Professor of
Environmental Policy at the Kennedy School of Government
at Harvard University, and also Professor of Environmental
Science and Public Policy in the Department of Earth and
Planetary Sciences. He earned a bachelor’s degree in physics
from MIT in 1965, and worked as a consultant on re-entry
vehicles in the 1960s at Lockheed Martin before receiving a
PhD in plasma physics at Stanford University in 1970. Since
then, his work has focused largely on science policy rather
than on fundamental physics, with emphasis on global
environmental change, energy technologies and policies,
nuclear proliferation, and science and technology policy in
general. He is a prominent and vigorous advocate for strong
response to the global climate crisis. Holdren is also director
of the Woods Hole Research Center in Woods Hole,
Massachusetts.
In many respects, this looked like a fine choice. Holdren has
a very distinguished record. Before moving to Harvard in
1996, he was Professor of Energy and Resources at Berkeley
for over 20 years. He was President of the American
Association for the Advancement of Science in 2006. He is the
author of over 300 articles and papers, mostly on policy
issues, and has co-authored or co-edited 20 books and book-
length reports. He is a member of the National Academy of
Sciences, the National Academy of Engineering, and was a
member of President Bill Clinton’s science advisory team from
1994 to 2001. When the Pugwash Conferences on Science and
World Affairs won the Nobel Peace Prize in 1995, he delivered
the acceptance speech in Stockholm. He’s spent much of his
career trying to save the planet. Sort of a scientist’s Al Gore, if
you will. It’s likely that he has more combined expertise on
climate science and clean energy technology than anyone, with
the possible exception of Obama’s nominee for Secretary of
Energy, Nobel Laureate Steve Chu. But when I heard of his
likely appointment, I was disappointed.
I wasn’t disappointed because I have anything against
Holdren - he’s certainly highly qualified and I love his
positions on issues like climate change. He’ll probably do a
terrific job. I was disappointed because he’s a physicist. No
disrespect to Holdren, but I am wary of physicists as
presidential science advisors. Nearly all have been so. It’s
partly a legacy from the days when they knew how to make
nuclear weapons, and partly, I think, because when most
non-scientists think about scientists, they tend to think of
physicists (call it the Einstein Effect). Most of the physicists I
know, and certainly all recent presidential science advisors,
have little knowledge of or feel for the life sciences, believe
physics to be superior to all other sciences (with the possible
exception of higher mathematics), and tend to think in terms
of big science programs as opposed to individual investigator-
initiated research. Certainly physics is important in issues
such as energy policy and response to climate change, and I
suspected that the Holdren appointment was meant to
emphasize the significance the Obama Administration
attaches to those issues, but we already have someone, of
cabinet rank with direct access to the President, with exactly
the same qualifications and mission as Holdren: a strong
physics background and a track record of vigorous advocacyfor alternative energy. I refer to the aforementioned Steve
Chu, the nominee for Energy Secretary. I didn’t understand
why we needed to duplicate that expertise and focus, when
the Presidential Science Advisor seemed to me the best
opportunity to bring someone knowledgeable about the life
sciences into the President’s inner circle. And if we ever
needed people in government to listen to the voices of the
life scientists, we need them now.
I believe it’s essential that there be people in Washington
who can explain to President Obama, for example, the
science that must be done to combat a coming global crisis
that is comparable in its effects to the climate crisis: the
rapidly aging population. Figure 1 shows what I mean. On
these maps I have colored in blue every country in which
more than 20% of the population is over 65 years of age.
The map on the left is the world we live in. The map on the
right, where virtually every country is blue, is the world our
children will live in. In most of the developed world, by
2050 at least a quarter of the people will be older than 65,
and in some countries that figure will exceed 40%. In the
US alone, there are more than 10 million people over the
age of 80 today; by 2050 there will be more than 30
million, and half of them will have some degree of
dementia. Another 3 million, at least, will have Parkinson’s
disease. Millions more will suffer from stroke. The
incidence of all three of these disorders rises exponentially
after age 65. The total cost of age-related neurological
diseases in the US is currently more than $300 billion a
year. In 40 years the annual cost will exceed a trillion
dollars. Yet the federal expenditure on AIDS research in
2008 is more than four times the federal expenditure on
Alzheimer’s disease research, despite the fact that there are
ten times more new Alzheimer’s cases per year than there
are AIDS cases. (This is not meant to imply that we’re
spending too much on AIDS research; my point is that
we’re not spending nearly enough on research into
age-related neurological diseases.) Heart disease and
cancer rates, too, are likely to increase in coming years,
because the vast majority of new cases of both occur in
people over age 65.
Aging of the population is a time-bomb that is ticking in
most of the world - an impending medical crisis of
magnitude similar to global warming. Health care reform, as
important as it is, will not solve this problem. Alternative
energy, as important as it is, will not solve it. The only thing
that will is biomedical research, both basic and applied.
I’m emphasizing the coming biomedical crisis because it is the
nature of people, and politicians, to focus on crises, but there
are many other reasons why the life sciences deserve a seat at
the table of power. The post-genomic revolution in our
understanding of biology has the power to transform all of our
lives. One of the answers to the climate crisis, and to the
problem of energy independence, is biofuels. Another
answer, which could wean us away from petroleum-based
plastics, is biomaterials. Basic biomedical research is essential
to arm our pharmaceutical and biotechnology companies for
the fight against weapons of biological warfare, as well as the
increasing threat from emerging infectious diseases. The life
sciences have central roles to play in addressing the collapse of
the environment, the disappearance of species, and our efforts
to combat developmental disorders, to name but a few areas of
importance. But when I started to write this column, I was
afraid that there would be no advocate for biomedical research
at that table where policy makers sit down to decide the
nation’s priorities.
Then something (well, actually, someone) told me to wait
until after the President-elect’s next radio address. I just
finished listening to it, and I urge you to read the transcript
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The rapidly aging world. ( (a a) ) The world today, showing in blue areas where greater than 20% of the population is over the age of 65. ( (b b) ) The world in
2050, showing the huge increase in areas where the population will be over 65 years old.
(a) Today (b) 2050
> 20% of population over age 65(you can find it, and a video, at http://change.gov/
newsroom/entry/the_search_for_knowledge_truth_and_a_
greater_understanding_of_the_world_aro/); it’s so unlike
anything we’ve heard from recent US Presidents as to be
almost revolutionary. Here are just two excerpts:
“Whether it’s the science to slow global warming; the
technology to protect our troops and confront bioterror and
weapons of mass destruction; the research to find life-saving
cures; or the innovations to remake our industries and
create twenty-first century jobs - today, more than ever
before, science holds the key to our survival as a planet and
our security and prosperity as a nation. It is time we once
again put science at the top of our agenda and worked to
restore America’s place as the world leader in science and
technology.”
“…promoting science isn’t just about providing resources -
it’s about protecting free and open inquiry. It’s about
ensuring that facts and evidence are never twisted or
obscured by politics or ideology. It’s about listening to what
our scientists have to say, even when it’s inconvenient -
especially when it’s inconvenient. Because the highest
purpose of science is the search for knowledge, truth and a
greater understanding of the world around us. That will be
my goal as President of the United States…”
President-elect Obama then went on to name the key
members of his science and technology team. One, as I
already expected, was John Holdren as Assistant to the
President for Science and Technology and Director of the
White House Office of Science and Technology Policy. He
would also, as is customary, chair the President’s Council of
Advisors on Science and Technology - or PCAST, a board
that advises the President on all matters pertaining to
science and technology. (Under George Bush, PCAST had
consisted almost entirely of CEOs of big corporations. It had
almost no scientific expertise at all.) But then came the
surprise: PCAST would have two additional co-chairs, and
both of them would be distinguished life scientists.
One is Harold Varmus, 1989 Nobel Laureate in Medicine or
Physiology for his work on cancer genes and former Director
of the National Institutes of Health during the Clinton
Administration - and during the completion of the Human
Genome Project. Arguably the most effective NIH Director
in decades, Varmus is currently President of the Memorial
Sloan-Kettering Cancer Center in New York City. The other
is Eric Lander, Professor of Biology at MIT, member of the
Whitehead Institute, the Founding Director of the Broad
Institute at MIT and Harvard, and one of the driving forces
behind the mapping and sequencing of the human genome.
Varmus probably needs no introduction from me, but some
of my readers may be a little less familiar with Lander. He is
one of those rare individuals who might just be as smart as
he’s supposed to be. A mathematical prodigy, he did his
doctoral work at Oxford University as a Rhodes Scholar. He
then taught economics at Harvard Business School before,
looking for new worlds to conquer, he did a postdoc in
genetics with David Botstein at MIT, joining the Biology
faculty there afterwards. He is - get ready for it - a genome
biologist, the first to have the ear of a President. Now you
might think, or even fear, that a genome biologist, especially
one who has built a mighty institute for large-scale
genomics, would not be an ideal friend for individual
investigator-initiated research, but let me set your mind at
ease. The ‘big’ science that Eric Lander has pioneered has
always been in the service of hypothesis-driven ‘small’
science, and his track record as Director of the Broad
Institute has been one of encouraging young investigators,
providing tools and information to the broader biological
community, and promoting basic as well as applied research.
Two better appointments could scarcely be imagined. Both
men are vigorous advocates for basic biomedical science,
both men know how the industry-academic partnership is
supposed to work, both men understand the way the age of
genomics is transforming the life sciences, and both men are
not so far removed from running research laboratories of
their own that they will not appreciate the problems of the
average scientist.
So for the next few years, at least, when policy makers in the
Obama Administration sit around that table to plan the
future of the country, the life sciences will have a seat
alongside the physical sciences. And a President who
promises to listen to the voice of science will be hearing the
full scope of that voice at last.
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